Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Food Effects of EC5026 in Healthy Subjects
NCT04908995Phase 1Completed
- Sponsor
- EicOsis Human Health
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing EC5026 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) at 77 days, Area under the plasma concentration versus time curve at 14 days and 9 more. Started Apr 2021; status: completed.
02
Drugs
EC5026
03
Conditions
pain
Beyond the preview
Go deeper on NCT04908995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908995.